TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25881456

Group type: COMPARATOR
Intervention: Telmisartan treatment group (80 mg per day, once daily)
Number of subjects: 204

Group type: COMPARATOR
Intervention: SG treatment group (5 g each time, 3 times per day)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Combination of SG and telmisartan treatment group (telmisartan 80 mg per day, once daily and SG 5 g each time, 3 times per day)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Combination of SG and telmisartan treatment group
Number of subjects: 204
Study: 24029859

Group type: EXPERIMENTAL
Intervention: Structured exercise programme
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: One-leg rise tests
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Vertical hop results
Number of subjects: 87
Study: 21335417

Group type: EXPERIMENTAL
Intervention: Letrozole monotherapy
Number of subjects: 6182

Group type: EXPERIMENTAL
Intervention: Letrozole→Tamoxifen
Number of subjects: 6182

Group type: EXPERIMENTAL
Intervention: Tamoxifen→Letrozole
Number of subjects: 6182

Group type: EXPERIMENTAL
Intervention: Tamoxifen monotherapy
Number of subjects: 6182
Study: 18570223

Group type: EXPERIMENTAL
Intervention: Advanced Practice Nurse (APN) intervention for 6 months
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: APN plus Psychiatric Consultation-Liaison Nurse (PCLN) intervention
Number of subjects: 123

Group type: COMPARATOR
Intervention: Attention control group (symptom management by a research assistant)
Number of subjects: 123
Study: 17536207

Group type: EXPERIMENTAL
Intervention: Fitness intervention focusing on functional skills, strength, endurance and flexibility
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Psychomotor intervention focusing on body awareness, body experience and coordination
Number of subjects: 217

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 217
Study: 15593039

Group type: EXPERIMENTAL
Intervention: BK-F Polymethylmethacrylate-based hemodialysis (BK-F-HD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-flux hemodialysis (LF-HD)
Number of subjects: 18
Study: 12143075

Group type: EXPERIMENTAL
Intervention: PLST intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison intervention
Number of subjects: 0
Study: 9562692

Group type: EXPERIMENTAL
Intervention: DTPa‐HB vaccine administered at 2, 4, and 6 months (group A)
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: DTPa‐HB vaccine administered at 3, 5, and 11 months (group B)
Number of subjects: 565
Study: 7708996

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP) at 8 cmH2O
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham pressure
Number of subjects: 16
Study: 2505631

Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 77

Group type: COMPARATOR
Intervention: halothane
Number of subjects: 77

Group type: COMPARATOR
Intervention: enflurane
Number of subjects: 77
Study: 1146927

Group type: EXPERIMENTAL
Intervention: Ethynylestradiol (EE) at 50 mug per day
Number of subjects: 4638

Group type: EXPERIMENTAL
Intervention: Mestranol at 50 mug per day
Number of subjects: 4638

Group type: EXPERIMENTAL
Intervention: Combination of very low doses (20 to 40 mug per day) of estrogen with various 19-nor progestins
Number of subjects: 4638

Group type: COMPARATOR
Intervention: Control cycles (no treatment)
Number of subjects: 4638
Study: 30844728

Group type: EXPERIMENTAL
Intervention: Beta-blocker titration (bisoprolol and carvedilol)
Number of subjects: 574
Study: 30158384

Group type: EXPERIMENTAL
Intervention: NK-104-NP (pitavastatin calcium) 1 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NK-104-NP (pitavastatin calcium) 2 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NK-104-NP (pitavastatin calcium) 4 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NK-104-NP (pitavastatin calcium) 8 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NK-104-NP (pitavastatin calcium) for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NK-104-NP (pitavastatin calcium)
Number of subjects: 40
Study: 27063525

Group type: EXPERIMENTAL
Intervention: Sutureless cryopreserved amniotic membrane graft (Prokera)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bandage contact lens (Acuvue Oasys)
Number of subjects: 40
Study: 25213566

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg daily for 3 months
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 53
Study: 22328479

Group type: EXPERIMENTAL
Intervention: Educational workshop on EMR documentation with embedded social marketing messages
Number of subjects: 155
Study: 20298497

Group type: EXPERIMENTAL
Intervention: certolizumab pegol 400 mg (week 0, 2, 4)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: certolizumab pegol 400 mg every 4 weeks until week 24
Number of subjects: 668

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 668
Study: 18069214

Group type: EXPERIMENTAL
Intervention: eMPC algorithm
Number of subjects: 20

Group type: COMPARATOR
Intervention: RP group
Number of subjects: 20
Study: 15714292

Group type: EXPERIMENTAL
Intervention: Modified lay-open technique (Group A)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Excision with primary closure (Group B)
Number of subjects: 142
Study: 11847615

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) coating
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-coated stems (Control)
Number of subjects: 20
Study: 9437314

Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.02 mg/ml)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gentamicin solution (0.3%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 50
Study: 7906330

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 32
Study: 2698568

Group type: EXPERIMENTAL
Intervention: 75 mg gallopamil (slow release) twice daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 779497

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline and psychotherapy
Number of subjects: 150
Study: 29984439

Group type: EXPERIMENTAL
Intervention: terbutaline pH 7.0
Number of subjects: 17

Group type: COMPARATOR
Intervention: terbutaline pH 4.3
Number of subjects: 17

Group type: COMPARATOR
Intervention: saline solution pH 7.0
Number of subjects: 17

Group type: COMPARATOR
Intervention: saline solution pH 4.3
Number of subjects: 17
Study: 28726510

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei Shirota (LcS)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study: 26247913

Group type: EXPERIMENTAL
Intervention: E-learning supported Train-the-Trainer program
Number of subjects: 566

Group type: COMPARATOR
Intervention: Usual implementation (control)
Number of subjects: 566
Study: 23245824

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) given immediately after BTX-A injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrical stimulation (ES) given immediately after BTX-A injections
Number of subjects: 0
Study: 21962476

Group type: EXPERIMENTAL
Intervention: Precontrast HiSS MRI
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional fat-suppressed MRI
Number of subjects: 54
Study: 18503840

Group type: EXPERIMENTAL
Intervention: Direct coronal images (DC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronal reformatted images with 1-mm axial collimation (CR1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronal reformatted images with 0.625-mm axial collimation (CR2)
Number of subjects: 0
Study: 16371497

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) at 5.4 J per point, power density 20 mW/cm2
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo LLLT (0 J)
Number of subjects: 7
Study: 12748498

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10921707

Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuits
Number of subjects: 42

Group type: COMPARATOR
Intervention: Uncoated cardiopulmonary bypass circuits
Number of subjects: 42
Study: 8822400

Group type: EXPERIMENTAL
Intervention: Sex education program based on cognitive social learning theory and social influence theory
Number of subjects: 2411

Group type: COMPARATOR
Intervention: Pretest
Number of subjects: 2411

Group type: COMPARATOR
Intervention: Intervention
Number of subjects: 2411
Study: 8079476

Group type: EXPERIMENTAL
Intervention: autohemotransfusions of ultraviolet‐irradiated blood (UVIB)
Number of subjects: 85
Study: 2485053

Group type: EXPERIMENTAL
Intervention: alpha-human ANP, 150 micrograms over 30 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: alpha-human ANP after acute CE inhibition by enalapril (EN) 20 mg P.O., 4 h before ANP infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31172685

Group type: EXPERIMENTAL
Intervention: AG10
Number of subjects: 0
Study: 29601846

Group type: EXPERIMENTAL
Intervention: Caregiver burden assessment at baseline, 3 months, and 12 months post-arrest using the Infant Toddler Quality of Life Questionnaire and the Child Health Questionnaire.
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Child functioning assessment using the Vineland Adaptive Behaviour Scales Second Edition (VABS‐II), Paediatric Overall Performance Category (POPC), and Paediatric Cerebral Performance Category (PCPC) scales.
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Global functioning assessment at 3 months post-arrest.
Number of subjects: 138
Study: 24361322

Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion
Number of subjects: 61
Study: 22863328

Group type: EXPERIMENTAL
Intervention: 5·0×10(6) cells per mL every 7 days
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 5·0×10(6) cells per mL every 14 days
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 0·5×10(6) cells per mL every 7 days
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 0·5×10(6) cells per mL every 14 days
Number of subjects: 205

Group type: COMPARATOR
Intervention: Vehicle alone every 7 days
Number of subjects: 205
Study: 19995096

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin aspart three times daily with or without NPH insulin
Number of subjects: 0
Study: 19408486

Group type: EXPERIMENTAL
Intervention: Enzymatic debridement using a proteolytic enzyme complex from pineapple stems
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard of care methods
Number of subjects: 22
Study: 16485522

Group type: EXPERIMENTAL
Intervention: High intensity exercise in trained subjects (T)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise in trained subjects (T)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low intensity exercise in untrained subjects (UT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise in untrained subjects (UT)
Number of subjects: 17
Study: 12439117

Group type: EXPERIMENTAL
Intervention: Post-infectious IBS or functional diarrhoea group (n=24)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 42
Study: 10480584

Group type: EXPERIMENTAL
Intervention: Extended release albuterol sulfate
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate
Number of subjects: 46
Study: 7586313

Group type: EXPERIMENTAL
Intervention: 125 mg intravenous amiodarone
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: 500 mg intravenous amiodarone
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: 1000 mg intravenous amiodarone
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: All doses of intravenous amiodarone
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 342
Study: 2334628

Group type: EXPERIMENTAL
Intervention: Nebulized lignocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of lignocaine vs saline
Number of subjects: 20
Study: 111610

Group type: EXPERIMENTAL
Intervention: Azlocillin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 20
Study: 30865295

Group type: EXPERIMENTAL
Intervention: Couple therapy
Number of subjects: 554
Study: 31666059

Group type: EXPERIMENTAL
Intervention: Generic drugs awareness
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Generic substitution knowledge
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Understanding of legislation
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Legislative rules awareness
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Drug-related problems awareness
Number of subjects: 1237
Study: 27816543

Group type: EXPERIMENTAL
Intervention: Pharmaceutical assistance programs (PAPs) for smoking cessation medications
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: PAP-eligible smokers
Number of subjects: 560
Study: 25403016

Group type: EXPERIMENTAL
Intervention: Enhancing Connections Program (5, 1-hr educational counseling sessions at 2-week intervals)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (received a booklet and phone call on communicating and supporting their child about the mother's cancer)
Number of subjects: 176
Study: 23550199

Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous needle aspiration along with metronidazole
Number of subjects: 57

Group type: COMPARATOR
Intervention: Metronidazole alone
Number of subjects: 57
Study: 21844082

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (2 g/d)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 19852201

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 34

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Budesonide + Terbutaline
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 34
Study: 16466310

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 14755039

Group type: EXPERIMENTAL
Intervention: Women with BV
Number of subjects: 890

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 890
Study: 11824362

Group type: EXPERIMENTAL
Intervention: Scientific research carried out by surgical department heads
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Retrospective studies and case studies
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Participation in prospective randomized studies
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Publications in German
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Publications in English
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Improved know-how and coordination centers
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lack of time and documentation issues
Number of subjects: 27
Study: 9423917

Group type: EXPERIMENTAL
Intervention: Lid speculum used during surgery (n = 108)
Number of subjects: 220

Group type: COMPARATOR
Intervention: No lid speculum used during surgery (n = 112)
Number of subjects: 220
Study: 8201689

Group type: EXPERIMENTAL
Intervention: In situ ESWL (Dornier HM3)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: In situ ESWL (Siemen's Lithostar)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ureteroscopy
Number of subjects: 76
Study: 3142430

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) intravenously (group 1)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Single-chain rt-PA (group 2)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Two-chain rt-PA (group 3)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: rt-PA followed by intracoronary streptokinase (group 4)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Acyl enzyme (group 5)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 163
Study: 29324233

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26873582

Group type: EXPERIMENTAL
Intervention: Motivational health promotion intervention adapted for persons with SMI
Number of subjects: 20
Study: 25708991

Group type: EXPERIMENTAL
Intervention: Attention bias modification treatment (ABMT)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Attention bias modification treatment (ABMT) delivered in clinic
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Attention bias modification treatment (ABMT) delivered at home
Number of subjects: 589

Group type: COMPARATOR
Intervention: Control training
Number of subjects: 589
Study: 23917696

Group type: EXPERIMENTAL
Intervention: Celiac plexus block performed after pharmacological control of pain (Group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Celiac plexus block performed first followed by pharmacotherapy (Group I)
Number of subjects: 60
Study: 20701121

Group type: EXPERIMENTAL
Intervention: Tpanax Notoginseng pills (4 g, twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tpanax Notoginseng pills (4 g, twice daily) and Lornoxicam injection (8 mg, once daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tpanax Notoginseng pills (4 g, twice daily), Lornoxicam injection (8 mg, once daily), and Tongmai decoction (200 ml, twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 60
Study: 18445842

Group type: EXPERIMENTAL
Intervention: Sorafenib plus dacarbazine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo plus dacarbazine
Number of subjects: 101
Study: 16571610

Group type: EXPERIMENTAL
Intervention: Breas PV 10i
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Autoset Spirit
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: RemStar Auto
Number of subjects: 27

Group type: COMPARATOR
Intervention: All APAP devices
Number of subjects: 27
Study: 14659344

Group type: EXPERIMENTAL
Intervention: Withdrawal of synthetic progestin (nomegestrol acetate or NOMAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous treatment with nomegestrol acetate (NOMAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Withdrawal of NOMAC
Number of subjects: 0
Study: 11143933

Group type: EXPERIMENTAL
Intervention: Closure of the visceral peritoneum
Number of subjects: 577

Group type: COMPARATOR
Intervention: Nonclosure of the visceral peritoneum
Number of subjects: 577
Study: 8775936

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting-enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic agents
Number of subjects: 0
Study: 1385826

Group type: EXPERIMENTAL
Intervention: Patch test reactions to 11 common organic allergens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patch test control (0.4% phenol and 50% glycerin in 0.9% saline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lesional skin samples
Number of subjects: 0
Study: 6338636

Group type: EXPERIMENTAL
Intervention: Antilymphoblast globulin (ALG)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (azathioprine and prednisone without ALG)
Number of subjects: 67
Study: 30778427

Group type: EXPERIMENTAL
Intervention: CT scans reviewed for anatomical variations
Number of subjects: 200
Study: 29121274

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV)/irinotecan (IRI)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard temozolomide
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard temozolomide with crossover to BEV second-line therapy
Number of subjects: 170
Study: 26698820

Group type: EXPERIMENTAL
Intervention: Psychotherapy (78 weeks)
Number of subjects: 100
Study: 25271049

Group type: EXPERIMENTAL
Intervention: β-blocker use in prior MI cohort
Number of subjects: 14677

Group type: EXPERIMENTAL
Intervention: β-blocker use in known atherothrombotic disease cohort
Number of subjects: 14677

Group type: EXPERIMENTAL
Intervention: β-blocker use in risk factors alone cohort
Number of subjects: 14677
Study: 21592719

Group type: EXPERIMENTAL
Intervention: Choice interactive tailored patient assessment tool (ITPA)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (no ITPA)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Nurses consultations
Number of subjects: 196

Group type: COMPARATOR
Intervention: Physicians consultations
Number of subjects: 196
Study: 21180869

Group type: EXPERIMENTAL
Intervention: National manovacuometer
Number of subjects: 18

Group type: COMPARATOR
Intervention: Foreign manovacuometer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Comparison of both manovacuometers
Number of subjects: 18
Study: 17979860

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) injections (3 injections at 0, 6, and 18 months; dose 0.5-2.1 units/kg, mean 1.5 [SD 0.18]; dilution 100 units/0.5 ml)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Delayed group (2 injections at 6 and 18 months)
Number of subjects: 42
Study: 14717945

Group type: EXPERIMENTAL
Intervention: Calcitriol therapy (0.5 microg/48 h) plus oral calcium supplementation (0.5 g/day) for 1 year
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Calcitriol therapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 11779900

Group type: EXPERIMENTAL
Intervention: Clomethiazole (68 mg/kg IV over 24 hours)
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Clomethiazole
Number of subjects: 1198
Study: 9639500

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) plus interleukin-2
Number of subjects: 0
Study: 7827649

Group type: EXPERIMENTAL
Intervention: 3 different drug regimes
Number of subjects: 0